Evolent Health (NYSE:EVH) Given New $19.00 Price Target at Barclays

Evolent Health (NYSE:EVH - Free Report) had its price objective lowered by Barclays from $39.00 to $19.00 in a report released on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the technology company's stock.

EVH has been the topic of several other reports. KeyCorp started coverage on Evolent Health in a research report on Friday, October 11th. They issued an "overweight" rating and a $35.00 price objective on the stock. Stephens downgraded shares of Evolent Health from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $38.00 to $16.00 in a research report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 price target on shares of Evolent Health in a report on Tuesday, October 8th. Citigroup reduced their target price on shares of Evolent Health from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, October 29th. Finally, Truist Financial reiterated a "buy" rating and set a $33.00 price objective on shares of Evolent Health in a research note on Tuesday, August 27th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $32.90.

Evolent Health Trading Up 13.2 %

NYSE EVH traded up $1.77 during mid-day trading on Monday, reaching $15.13. 8,472,986 shares of the stock were exchanged, compared to its average volume of 1,737,112. The stock has a market capitalization of $1.76 billion, a PE ratio of -16.09 and a beta of 1.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.08 and a current ratio of 1.08. Evolent Health has a 1-year low of $13.31 and a 1-year high of $35.00. The business's fifty day simple moving average is $26.84 and its 200 day simple moving average is $24.80.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.21 by $0.09. Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.27%. The firm had revenue of $647.10 million during the quarter, compared to analyst estimates of $636.46 million. During the same quarter in the prior year, the business posted $0.06 earnings per share. Evolent Health's revenue for the quarter was up 37.9% compared to the same quarter last year. On average, research analysts anticipate that Evolent Health will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Evolent Health

In related news, President Daniel Joseph Mccarthy sold 23,693 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the transaction, the president now directly owns 198,809 shares in the company, valued at $6,141,210.01. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, General Counsel Jonathan Weinberg sold 42,140 shares of the company's stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $31.20, for a total value of $1,314,768.00. Following the sale, the general counsel now directly owns 167,027 shares in the company, valued at approximately $5,211,242.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the firm's stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the transaction, the president now owns 198,809 shares of the company's stock, valued at $6,141,210.01. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 307,291 shares of company stock valued at $9,290,385 in the last ninety days. Company insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of EVH. Scout Investments Inc. acquired a new position in shares of Evolent Health during the first quarter worth approximately $5,760,000. Harbor Capital Advisors Inc. boosted its position in Evolent Health by 140.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company's stock valued at $11,946,000 after buying an additional 246,400 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Evolent Health by 11.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company's stock valued at $23,522,000 after buying an additional 75,376 shares during the period. Valeo Financial Advisors LLC bought a new stake in shares of Evolent Health during the second quarter worth $2,705,000. Finally, Gabelli Funds LLC lifted its stake in shares of Evolent Health by 21.5% during the first quarter. Gabelli Funds LLC now owns 638,500 shares of the technology company's stock valued at $20,936,000 after acquiring an additional 113,000 shares during the period.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.